At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses Trial Assigning IndividuaLized Options for Treatment (TAILORx), a prospective phase 3 clinical trial that was designed to evaluate the utility of the Oncotype DX® Breast Cancer Assay to risk stratify patients with oestrogen receptor-positive, HER2-negative, node-negative breast cancer. By identifying low-risk patients who are unlikely to benefit from adjuvant chemotherapy, the test may allow physicians to direct patients to individualised therapies that are associated with improved health outcomes.
This content is supported by Genomic Health, Inc.
